Omega Therapeutics, Inc.

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings. “These preclinical results build upon the foundation of data we have shared to date and expand our confidence in the ability of epigenomic controllers to upregulate or downregulate the expression of one or more genes,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. “More broadly, we believe these upcoming presentations further demonstrate the power of the OMEGA platform to prospectively engineer novel therapeutic candidates to regulate gene expression with high specificity and the potential of precision epigenomic control to offer new treatment strategies for diverse indications.” Details for the upcoming presentations are as follows: Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, TX, November 8 – 10 Title: Controlled Epigenetic Upregulation of CXCL9 and CXCL10 in Hepatocellular Carcinoma Promotes T-cell RecruitmentAbstract Number: 1360Session Date and Time: Saturday, November 9, 2024, from 12:15 to 1:45 p.m. CST Poster and Flash Talk at the 12th International mRNA Health Conference taking place in Boston, MA, November 12 – 14 Title: Programmable Epigenomic mRNA Therapeutics Enable Multi-Gene Up or Down Tuning of α-globin via Regulatory Element Targeting: A Precision Approach for β- and α-Thalassemia TreatmentPaper Number: 102E-Poster Session Date and Time: Tuesday, November 12, 2024, beginning at 9:00 a.m. ESTFlash Talk Session Date and Time: Tuesday, November 12, 2024, from 4:00 to 5:00 p.m. EST Poster at the American Association for the Study of Liver Diseases’ (AASLD) 75th Annual The Liver Meeting® taking place in San Diego, CA, November 15 – 19 Title: Durable Upregulation of P1-isoform Hepatocyte Nuclear Factor 4 alpha (HNF4α) Using Novel Epigenomic ControllersPublication Number: 3228 Session Title: MASLD/MASH - Therapeutics: New AgentsSession Date and Time: Sunday, November 17, 2024, from 8:00 a.m. to 5 p.m. PST The posters will be made available on the Omega website at https://omegatherapeutics.com/science/publications/ at the same time as the respective presentations. About Omega Therapeutics Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions. For more information, visit omegatherapeutics.com, or follow us on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our expectations surrounding the broad potential of precision epigenomic control, the versatile capabilities of the OMEGA platform, the potential of the Company’s pipeline of therapeutic candidates, and the Company’s participation in upcoming events and presentations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controllers due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; volatility in capital markets and general economic conditions; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; potential delays in and unforeseen costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; difficulties manufacturing the novel technology on which our epigenomic controller candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner Emeritus at McKinsey & Company, where he has advised companies in advanced industries for more than 30 years. Andonian's background in driving strategic transformations across diverse industries aligns perfectly with Invaio's mission to revolutionize agriculture by providing farmers with more natural crop protection. "We are thrilled to have André take on the role of Chairman. His deep understanding of global industries, strategic acumen, and passion for sustainable solutions make him the ideal leader to guide Invaio into its next phase of growth and innovation," said Ignacio Martinez, General Partner at Flagship Pioneering. "I would also like to thank Robert for his important contribution to Invaio over the last five years and look forward to our continued collaboration." In addition to his role at McKinsey, Andonian has also held influential positions in various industries, including serving on the boards of leading companies, foundations and educational institutions. "I am honored to take on the role of Chairman at Invaio Sciences," said Andonian. "The company's approach to agriculture, grounded in cutting-edge science and a deep respect for nature, is truly transformative. I look forward to working with the team to accelerate Invaio's impact on sustainable agriculture, ensuring a healthier and more productive future for farmers and consumers alike." As Chairman, Andonian will play a key role in guiding Invaio's strategic direction, fostering partnerships, and scaling its innovative solutions to meet the challenges of modern agriculture. His appointment reflects Invaio's continued dedication to building a leadership team with the expertise and vision to drive meaningful change in the global agricultural sector. About André Andonian André Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering. He has over three decades of experience advising companies around the globe on a broad range of strategic, operational, and organizational topics, with a longstanding presence in the APAC region.   Andonian is Senior Partner Emeritus at McKinsey & Company, where he worked for 34 years, including as Senior Partner, Chairman of Japan, and Managing Partner of Korea. He also led Client Impact & Experience across Asia and was a member of McKinsey's leadership teams in Asia, Europe, and the United States, advising clients in the high-tech, industrial, automotive & assembly, aerospace, basic materials, biotech, and private equity sectors. He was a long-term member of the firm's global board and held extensive additional senior leadership roles in support of growth, people, and overall knowledge development.  Prior to joining McKinsey, Andonian worked at Masco Corporation in the US and at IBM in Austria, Spain, and the Middle East.   Andonian also serves as an Independent Director of the Board of ADI, Chair of the Board of Cognaize in the US, and NC Chair of AEM Holdings in Singapore. He is a member of the Advisory Board of the Sports & Health Sciences Department of the Technical University of Munich, chairs the Foundation for Armenian Science and Technology, and is a Special Advisor to the American Chamber of Commerce in Korea.   As a Fulbright Scholar, Andonian received an MBA at the Wharton School of the University of Pennsylvania, an MA and BA in Social & Economic Sciences as well as a BSc in Engineering, all with highest distinction, from institutions in his hometown of Vienna, Austria.   About Invaio Invaio Sciences, a Flagship Pioneering company, is a bioplatform company accelerating the leap to nature-positive agriculture. The company builds on advances in human health and digital innovation to develop biological technologies for crop health, enabling farmers to both improve yields and use more natural crop health solutions. Invaio is addressing consumer demands and unlocking radical benefits for farmers and the environment, leaving every acre better today and for generations to come. For more information, please visit or follow Invaio on X (Twitter) or LinkedIn. About Flagship Pioneering Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value. To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics. SOURCE Invaio Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 2, 2024 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, and Flagship Pioneering, the bioplatform innovation company, today announced plans to collaborate to advance health and sustainability outcomes in Singapore and the broader Asia Pacific region. In this collaboration, A*STAR and Flagship will jointly commit up to SGD100 million over the next five years. Continue Reading A*STAR and Flagship team members sign Memorandum of Understanding. A*STAR and Flagship outlined the goals of their collaboration via a Memorandum of Understanding (MOU) signed Tuesday. The collaboration will promote research and development activities between A*STAR research institutes and Flagship portfolio companies, to co-develop technologies in strategically important areas. Talent development is another pillar of the collaboration, with potential scientific dialogues and internship opportunities at Flagship and its portfolio companies. Together, A*STAR and Flagship seek to spur innovation and venture creation activities that help create and grow Flagship companies in Singapore. Flagship will contribute its signature approach to company creation and development while A*STAR will contribute its expertise in science and technology through access to its scientists and facilities. This MOU will have the potential to expand and foster collaborations among key players across Singapore's biotech ecosystem. "By joining forces, Flagship and A*STAR can further boost the already thriving life sciences ecosystem in Singapore and beyond, with breakthrough research, purposeful entrepreneurship and accelerated talent development," said André Andonian, Chair of Asia Pacific and Strategic Advisor, Flagship Pioneering. "This collaboration blends scientific acumen and entrepreneurial spirit and will further accelerate and expand Flagship's impact globally. We are pleased to announce this collaboration with A*STAR within the first year of opening our new Asia Pacific hub, located in Singapore." "We are excited to be working with globally-recognized venture builders like Flagship Pioneering, to bring new companies with cutting-edge technologies in areas of strategic interest to Singapore," said Irene Cheong, Assistant Chief Executive at A*STAR's Innovation & Enterprise Group. "This collaboration is a key step in nurturing our entrepreneurial talent and exploring new, innovative approaches to venture building. As we continue to expand these partnerships, we are confident that they will drive significant growth in Singapore's innovation landscape and advance Singapore's position as a global hub for biotechnological innovations." About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit . About Flagship Pioneering Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value. To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics. Media Contacts: Flagship Pioneering [email protected] A*STAR [email protected] SOURCE Flagship Pioneering WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED